MiR-495 regulates cell cycle and senescence by targeting CTRP3 to inhibit HCC cell growth, and in vivo assays illustrate that miR-495 has a better therapeutic effect on HCC in xenograft 34. Here, C1QTNF3 is linked to hepatocellular carcinoma.